Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
CMS Announces 6-Month Enrollment Moratorium on Home Health and Hospice Providers
The Centers for Medicare & Medicaid Services (CMS) announced a six‑month nationwide moratorium that blocks enrollment of new home health agencies and hospice providers, effective immediately. The pause is tied to Vice President JD Vance’s Anti‑Fraud Task Force and is intended to strengthen fraud detection in the sector. The American Hospital Association (AHA) expressed support for anti‑fraud efforts but warned the blanket restriction could worsen access to post‑acute care, especially in rural and underserved communities. CMS has been urged to adopt a more targeted, data‑driven approach.
Hantavirus Response Spans 2 US Biocontainment Facilities: 6 Updates
The CDC has declared a level‑3 emergency after an Andes hantavirus outbreak on the MV Hondius cruise ship, prompting U.S. health officials to monitor 18 American passengers. Sixteen are housed at the University of Nebraska Medical Center’s biocontainment and quarantine units,...
Majestic Care Sees Nursing Home Recruitment, Quality Gains Through Certification Push
Majestic Care partnered with the American Association of Post‑Acute Care Nursing to offer AAPACN certifications, beginning with MDS coordinators and expanding to medical directors. The company now requires its MDS coordinators to obtain the RAC‑CT credential, a move that coincided...
Healthcare Dashboards That Change Decisions | ClearPoint | ClearPoint Strategy Blog
ClearPoint’s latest blog explains why most healthcare dashboards focus on activity rather than outcomes and outlines a four‑phase rollout that drives adoption. It identifies five essential KPI categories—clinical quality, operational efficiency, financial health, patient experience, and workforce—and shows how Southern...
AI Uses 12-Lead ECGs to Predict Long-Term Stroke Risk
Researchers at Brigham and Women’s Hospital and its Boston affiliates have unveiled ECG2Stroke, an AI model that reads standard 12‑lead electrocardiograms to forecast long‑term ischemic stroke risk. Trained on data from more than 100,000 patients, the convolutional neural network achieved...
Turnover Runs High at 22% for Early-Career Nurses: Press Ganey
Press Ganey’s State of Nursing 2026 report finds U.S. hospitals lose $5.19 million per year on average due to registered nurse turnover. Overall nursing turnover remains at 17%, unchanged from prior years, while early‑career nurses experience a 22% departure rate. Millennials,...
PA Workforce Surpasses 201,000: Report
The National Commission on Certification of PAs reports that the U.S. physician‑assistant workforce reached 201,038 at the end of 2025, a 5.9% increase over the prior year and more than double the 2013 figure. The density rose to 59 PAs...
Mental Health Awareness Week Calls for Action as TPN.health Launches Real‑Time Access Platform
The Mental Health Foundation’s 2026 Mental Health Awareness Week (May 11‑17) shifted its theme to “Action,” urging measurable steps to close the mental‑health gap. At the same time, TPN.health introduced a real‑time Care Navigation system that reduces first‑appointment wait times to...
FDA Launches Public Call to Accelerate Drug Repurposing for Rare and Chronic Diseases
The U.S. Food and Drug Administration announced a formal request for public input on drug‑repurposing, aiming to speed new indications for approved medicines that address unmet medical needs. Commissioner Marty Makary highlighted the shortage of treatment options and the potential...
FDA Approves Rocket's Kresladi, First Gene Therapy for Ultra‑Rare LAD‑1
Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Kresladi, its inaugural gene‑therapy product, to treat leukocyte‑adhesion deficiency type 1 (LAD‑1). The approval marks the first gene‑editing treatment for this ultra‑rare pediatric immunodeficiency and signals a new commercial...
PREVENT and SCORE2 Prediction Tools Perform Well in Global Cohort
The American Heart Association’s PREVENT risk equations and Europe’s SCORE2 calculators were validated in a new global cohort of over 2 million patients, bringing the total validation sample to more than 8 million individuals. Both tools demonstrated moderate to favorable discrimination, with...
Wearable Sweat Sensor Monitors Multiple Biomarkers Continuously for 21 Days
University of California, Irvine researchers unveiled the IREM‑W₂MS₃, a battery‑free, wireless wearable patch that continuously monitors cortisol, glucose, lactate and urea in sweat for up to 21 days. The device regenerates its sensing surface via low‑voltage pulses, preventing performance loss...
A Simple X-Ray Measure Linked to Survival in Lung Cancer Surgery Patients
A retrospective study of 302 lung‑cancer patients with obstructive ventilatory disorder found that pre‑operative diaphragmatic dome height (DDH) measured on routine chest X‑rays predicts long‑term survival. Patients with low DDH had a 70% three‑year overall survival rate versus 85% for...
Study Validates Accuracy of Depression Screening for People with Chronic Pain
A new study published in the Journal of Affective Disorders confirms that the eight‑item Patient Health Questionnaire (PHQ‑8) reliably screens for depression in both chronic‑pain sufferers and those without pain. Researchers examined nearly 32,000 U.S. adults from the 2019 National...
Sonrotoclax Granted Accelerated Approval for R/R Mantle Cell Lymphoma
The FDA granted accelerated approval to BeOne Medicine’s sonrotoclax, marketed as Beqalzi, for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior therapies, including a BTK inhibitor. In the single‑arm BGB‑11417‑201 trial of...
5 Key Regulatory Shifts From Makary's Era at the FDA
Former FDA commissioner Marty Makary reshaped U.S. drug regulation with five sweeping changes: the agency dropped the default two‑trial requirement, making a single pivotal study the norm for most new drugs; a new biosimilar guidance eliminates routine comparative efficacy trials,...
TEFCA and CMS-Aligned Networks: Inflection Point for Digital Quality Measurement or Fragmentation Risk?
The Trusted Exchange Framework and Common Agreement (TEFCA) is expanding nationwide data exchange while CMS‑aligned networks are piloting FHIR‑based interoperability in real‑world settings. Together they promise a scalable foundation for digital quality measurement, shifting reporting from retrospective to actionable insights....
PTS Diagnostics Product Discontinuation Notice
PTS Diagnostics announced that its A1CNow+ Controls (REF 737) will be discontinued in the United States and the Maldives effective June 1, 2026, citing supply‑chain constraints. The company will continue to support existing inventory until each lot’s labeled expiration date and stresses the...
Can Clonal Hematopoiesis Improve Blood Cancer Screening?
Clonal hematopoiesis (CH) is emerging as a measurable precursor to aggressive blood cancers such as acute myeloid leukemia (AML). Recent research shows that high‑risk CH mutations can be detected with a simple $250 next‑generation sequencing blood test, and machine‑learning models...
Race, Risk, and the VBAC Calculator: The Politics of Race Correction in Childbirth
The article examines how the original MFMU VBAC calculator incorporated race, assigning lower predicted success rates to Black and Hispanic women, influencing counseling and contributing to higher cesarean rates among these groups. It traces the historical use of race in...
Re: King’s Speech: Government Unveils NHS Modernisation Bill Amid Labour Turmoil
The UK government’s NHS Modernisation Bill aims to introduce a single electronic patient record that clinicians can access anywhere. Earlier attempts under the Blair administration faltered due to public privacy fears, but today patients appear more receptive and technology is...
New Blood Test for Early Alzheimer’s Detection with FNIH’s Dr. Alessio Travaglia — Episode 255
A new blood test developed by the Foundation for the National Institutes of Health (FNIH) can predict Alzheimer’s symptom onset three to four years in advance, according to a study published in Nature Medicine. The test leverages a clock‑model biomarker...
Teaching Your Body To Make Designer Antibodies
A study published in Science demonstrates that a handful of gene‑edited blood‑forming stem cells can turn the body into a self‑sustaining factory for designer antibodies. In mice, as few as 7,000 edited cells produced therapeutic antibody levels that were boosted...
Omnia Inventa Introduces LNL300 for Lymph Node Retrieval
Omnia Inventa Medical has launched the Lymph Node Locator 300 (LNL300), a benchtop, FDA class I, 510(k)-exempt device that standardizes lymph node retrieval from fatty oncologic specimens. The system employs an acetone compression technique to strip fat and produce a...
FDA Approves Grifols Malaria Blood Screening Assay
The U.S. Food and Drug Administration has cleared Grifols’ Procleix Plasmodium assay for malaria screening of blood donors. The nucleic‑acid test uses magnetic target capture, transcription‑mediated amplification and chemiluminescence to identify ribosomal RNA from five human‑infecting Plasmodium species. It runs on...
International Medical Graduates Need Real Protections
International medical graduates (IMGs) face systemic barriers that left a Fulbright‑trained physician unable to help during the COVID‑19 surge because licensing exams were incomplete. After matching into a prestigious pediatrics residency, the author encountered a hostile culture where dissent was...
WATCH: Axios' Future of Health Summit 2026
Axios Live is hosting its second annual Future of Health Summit, gathering leaders across health care, pharma, technology, and policy to explore how a shifting landscape is redefining the industry. The event features a high‑profile roster, including Bristol Myers Squibb CEO...
Is Argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy?
Argenx SE (NASDAQ:ARGX) announced that the FDA has broadened Vyvgart and Vyvgart Hytrulo to treat all serotypes of adult generalized myasthenia gravis, including anti‑AChR, anti‑MuSK, anti‑LRP4 and triple‑seronegative patients. In its Q1 2026 report, the company posted $1.3 billion in global product...
Insmed Incorporated (INSM) Reports Q1 2026 Results
Insmed Incorporated reported first‑quarter 2026 revenue of $306 million, powered by $207.9 million from its BRINSUPRI antibiotic and $98.1 million from ARIKAYCE for non‑tuberculous lung disease. BRINSUPRI sales jumped 44% sequentially, while ARIKAYCE grew 6% year‑over‑year, reflecting expanding international uptake. The company reaffirmed...
Owkin, AstraZeneca Expand Collaboration on AI-Driven Drug Research Tools
Owkin has signed a three‑year licensing deal with AstraZeneca to provide its K Pro AI Scientist platform. The agreement will see Owkin build AI agents that plug into AstraZeneca’s IT environment to deliver competitive‑intelligence insights on targets, drug assets and clinical...
Sanofi Bets $294M on Toronto AI Hub
Sanofi is committing roughly US$218 million (CAD 294 million) to expand its Toronto Artificial Intelligence Centre of Excellence, adding 50 machine‑learning positions and bringing its digital workforce in Ontario to more than 150 by 2028. The province is contributing a conditional grant of...
ASCO Treatment Framework for Management of Mantle Cell Lymphoma Calls for Individualized, Risk-Adapted Therapy
At ASCO 2026, leading hematologists presented a new treatment framework for mantle‑cell lymphoma that emphasizes individualized, risk‑adapted therapy. The authors reaffirm the MIPI/MIPI‑c indices and incorporate Ki‑67, TP53 mutation, and MRD monitoring to refine patient stratification. In frontline therapy, adding...
Development of Local Anesthetic Drug Products With Prolonged Duration of Effect
The FDA released a draft Level 2 guidance (Docket FDA‑2023‑D‑0608) on developing local anesthetic products with prolonged duration of effect. The document outlines recommended development pathways, trial designs, and data requirements for future new‑drug applications. It aims to help sponsors generate evidence...
Brain Signal Predicts and Restores Attention in Children
Researchers at SickKids identified a millisecond‑scale brain signal that predicts attention lapses in children. Using machine‑learning on intracranial recordings, they created a closed‑loop system that delivers a brief electrical pulse exactly when the signal appears, instantly restoring focus. The same...
Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer
Cellares, an integrated development and manufacturing organization, has partnered with ProTgen to automate the production and quality control of ProT-096, a personalized progenitor T‑cell therapy for refractory leukemia and other blood cancers. Cellares will deploy its Cell Shuttle and Cell...
Moderna Tops TIME's 2026 Most Impactful Companies List
This week, @TIME ranked @moderna_tx #1 on its list of the World’s Most Impactful Companies of 2026. To create the ranking, TIME and @StatistaCharts analyzed economic and scientific data to determine which companies most effectively turn resources into value for people...
Advocates Urge FDA to Fast‑Track Ultra‑Rare Treatments
Powerful plea from @TPirovolak41022 to @US_FDA to expedite therapies for ultra-rare diseases #ASGCT2026 #CureSPG50 https://t.co/FTCTgn5TqH
Current Clinical Trials of Alzheimer’s Drugs
The 2026 annual report on Alzheimer’s drug development lists 158 therapies across 192 active clinical trials, enrolling 54,728 participants. Over the past decade the number of trials and tested agents grew by roughly 35% and 40%, respectively, with 59 new...
Metformin Shows Potential to Prevent Esophageal Cancer
Metformin Use and Development of Esophageal Squamous Cell Carcinoma "These findings suggest metformin use may have preventive potential against ESCC, which warrants further evaluation," [though this is a case-control study, would benefit from prospective design] https://t.co/w5QmYd9i55
FDA Clears ArteraAI Breast, First AI Tool to Guide Chemotherapy for Early‑Stage Breast Cancer
Artera announced FDA clearance of its ArteraAI Breast digital pathology risk‑stratification tool, the first AI‑driven test approved to guide chemotherapy decisions for early‑stage hormone‑receptor‑positive, HER2‑negative breast cancer. The multimodal model, trained on data from more than 8,500 patients, provides oncologists...
C Smith, C Kotzen, C Suttner, P Ndebele and M Cohen
A new study links extreme temperature events to measurable spikes in healthcare utilization, showing that heatwaves and cold snaps drive higher emergency department visits and hospital admissions. Researchers from South Africa quantified the relationship, finding that each degree Celsius above...
Medicare Launches $50 Copay Pilot, Giving Millions Access to GLP‑1 Weight‑Loss Drugs
Medicare announced an 18‑month GLP‑1 Bridge pilot that will let eligible Part D enrollees obtain weight‑loss drugs such as Wegovy for a $50 monthly copay, a roughly 95% price cut. The program, beginning July 1, aims to test broader coverage and could...
Halozyme Launches $1 Billion Share Buyback as Q1 Earnings Beat Expectations
Halozyme Therapeutics reported Q1 2026 revenue of $377 million, up 42% year‑over‑year, and announced a $1 billion share repurchase authorization, with at least $400 million slated for 2026. The earnings beat and aggressive capital return plan underscore management’s confidence in growing ENHANZE royalties...
One in Seven in UK Prefer Consulting AI Chatbots to Seeing Doctor, Study Finds
A study by King’s College London of over 2,000 UK adults found that 15% turn to AI chat‑bots for health advice instead of visiting their GP, with one‑quarter citing long NHS waiting lists as a driver. The research also revealed...
Lilly Data Point to ‘Maintenance’ Strategies for GLP-1 Weight Loss
Eli Lilly presented new data showing its GLP‑1 therapies can help patients maintain weight loss after injectable treatment. In the Surmount‑Maintain trial, patients who stayed on the highest Zepbound dose lost an additional two pounds over a year, while a reduced...
Clarification Needed of NHS Supply Chain Commitment to Value-Based Procurement
A recent NHS Supply Chain article claims value‑based procurement (VBP) will become the backbone of future purchases, yet a cardiology and vascular tender applied a 70% price weighting and a hard price‑threshold that could discard bids regardless of their demonstrated...
EU Pitches International Vaccine Supply-Chain Plan, Amid Hantavirus Warnings
The European Commission unveiled a Global Health Resilience Initiative, committing billions of euros (≈ $1.1 billion per euro) to diversify vaccine supply chains and bolster health services worldwide. Commissioner Jozef Sikela linked the move to a rising hantavirus outbreak and warned...
AMX-883
Amphista Therapeutics announced AMX-883, an oral degrader that recruits the DCAF16 E3 ligase to eliminate the epigenetic reader BRD9. The preclinical program demonstrates selective BRD9 degradation in acute myeloid leukemia (AML) cell models, leveraging a previously identified BRD9 binder for...
J&J Launches Improved Shockwave Catheter
Johnson & Johnson introduced the Shockwave C2 Aero, the fifth‑generation intravascular lithotripsy catheter designed to treat complex calcified coronary lesions. The new device offers greater flexibility and easier repositioning, expanding its use across a broader range of cases. It is already...
Why Attend the 2026 Canadian Pharma & Biotech PPM Summit Toronto
The Canadian Pharma & Biotech Project, Program and Portfolio Management Summit will convene senior life‑science leaders in Toronto on May 27‑28, 2026. Attendees will explore how to strengthen portfolio performance amid pricing pressure, evolving regulations, and intensified competition for global...